EP0767834A1 - Cassette d'expression de sequences antisens et de ribozymes - Google Patents

Cassette d'expression de sequences antisens et de ribozymes

Info

Publication number
EP0767834A1
EP0767834A1 EP95919314A EP95919314A EP0767834A1 EP 0767834 A1 EP0767834 A1 EP 0767834A1 EP 95919314 A EP95919314 A EP 95919314A EP 95919314 A EP95919314 A EP 95919314A EP 0767834 A1 EP0767834 A1 EP 0767834A1
Authority
EP
European Patent Office
Prior art keywords
ribozyme
expression cassette
loop region
antisense
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95919314A
Other languages
German (de)
English (en)
Inventor
Andre Lieber
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of EP0767834A1 publication Critical patent/EP0767834A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Definitions

  • the invention relates to a vector for antisense and for ribozyme expression.
  • Fields of application of the invention are molecular biology, genetic engineering and medicine.
  • RNA inactivation by antisense molecules or by ribozymes seems to be feasible for therapeutic use. Both classes of compounds can be made by chemical synthesis or in conjunction with a promoter by biological expression in vitro or even in vivo.
  • RNA molecules and cleavage in trans The principle of catalytic self-cleavage of RNA molecules and cleavage in trans has become well established in the past 10 years.
  • the hammerhead ribozymes are best characterized within the RNA molecules with ribozyme activity. After it has been shown that hammerhead structures can be integrated into heterologous RNA sequences and thereby transfer the ribozyme activity to this molecule, it seems obvious that catalytic antisense sequences can be provided for almost every target sequence with a matching cleavage site.
  • the basic principle of the ribozyme equipment is very simple: You select a region of interest of the RNA that contains the triplet GUC (or CUC), take 2 oligonucleotide strands with 6-8 nucleotides each and insert the catalytic hammerhead sequence in between .
  • Molecules of this type have been synthesized for numerous target sequences, they have shown catalytic activity in vitro and in some cases also in vivo. The best results were achieved with short ribozymes and target sequences.
  • a current challenge for in vivo use is the construction of ribozyme genes that allow continuous expression of the ribozyme in a specific cell (Bertrand, E. et al. / 1994 / Nucleic Acids Res. 22, 293-300).
  • the mRNA substrate probably exists in a strongly folded structure, which can also be protected by proteins bound to parts of the structure. Meeting accessible locations within the substrate for hybridization with the complementary flanking regions of the ribozyme is a matter of current probability.
  • Computer-aided predictions of possible thermodynamically stable secondary structures can be useful for finding loop regions without base pairing, but the physiological relevance of these conformation models is still uncertain.
  • the ribozyme Since the target raRNA is immediately transported out of the cell nucleus, the ribozyme must also pass into the cytoplasm, preferably in the same way. However, colocalization of ribozymes and their substrate is difficult to achieve.
  • ribozymes in vivo requires the insertion of ribozyme genes in suitable expression cassettes.
  • the transcription of these constructs can produce mRNAs that contain the central catalytic secondary structure of the ribozymes other, more stable base pairings within the non-complementary flanking sequences are displaced.
  • the kinetics of the cleavage reaction and the ability of the ribozymes to carry out multi-conversion reactions depend on the binding parameters and the structure of the complementary flanking regions of the ribozymes.
  • Cellular proteins can affect the catalysis of the cleavage reaction, probably by dissociating the ribozyme from the cleavage substrate, which is the precursor to the next cleavage.
  • the aim of the invention is to construct a vector for antisense and ribozyme expression. It should be able to bring about continuous and stable expression in a cell of a specific desired ribozyme or an antisense sequence.
  • a strong promoter preferably a T7 promoter
  • Subclaims 2-5 contain the preferred variants of the expression cassette.
  • the T7 promoter is preferably used in combination with T7 polymerase.
  • the loop region is located in a restriction site in the central part of the adenoviral va RNA gene, its size is at least 2x21 bases of the same sequence.
  • a preferred base sequence of the loop region is 5'-AACCCAGGTGTGCGACGTCAG-3 '.
  • Figure 2 shows the result of the cleavage of hGH RNA by a specific ribozyme in vitro.
  • A Structure of the specific ribozyme for a 27 n.t. Region around the GUC at position 988 within exon IV of hGH RNA.
  • B Maps of plasmid matrices for ribozyme synthesis by in vitro transcription with pol III (HeLa-extract) and T7-RNA polymerase.
  • C Electrophoretic representation of the fission products.
  • hGH-RNA was synthesized from a linear (Sstl section) genomic hGH gene (1663nt) by in vitro transcription with T7-RNA polymerase (with 0.2 ⁇ Ci 3 P CTP / ⁇ g RNA). An equi-ol mixture (100 nM) of ribozyme and substrate was incubated at 37 ⁇ C in 50 M Tris-Cl pH 7.5 and 10 mm MgCl 2 for 30 min with previous heat denaturation (90 sec 95 ⁇ C).
  • RNAs were purified and separated individually on a 6% PAA gel. Full length RNA and ribozyme cleavage products (988nt and 675nt) have been detected. The result shows that embedding the catalytic hammerhead structure in a stabilizing RNA (above all) leads to a functional and stable ribozyme only after the loop region has been additionally incorporated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le but de l'invention est de construire un vecteur d'expression de séquences antisens et de ribozymes. Il faut que le vecteur puisse exprimer de manière continue et stable un ribozyme ou une séquence antisens déterminés voulus dans une cellule. L'invention a des applications en biologie moléculaire et en génie génétique. La cassette d'expression décrite se caractérise en ce qu'elle contient un promoteur puissant, de préférence un promoteur T7, un gène va-ARN adénoviral, une région à boucle stable et un site d'insertion de séquences antisens ou de ribozymes dans la région à boucle. Le promoteur T7 est de préférence associé à une polymérase T7. La région à boucle se situe dans un site de restriction dans la partie centrale du gène va-ARN, et elle a de préférence au moins 2x21 bases de même séquence.
EP95919314A 1994-07-04 1995-05-19 Cassette d'expression de sequences antisens et de ribozymes Ceased EP0767834A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4424761A DE4424761C1 (de) 1994-07-04 1994-07-04 Expressionskassette für die Antisense- und die Ribozym-Expression
DE4424761 1994-07-04
US08/314,588 US5695992A (en) 1994-07-04 1994-09-28 Expression cassette for antisense expression of ribozyme
PCT/DE1995/000663 WO1996001315A1 (fr) 1994-07-04 1995-05-19 Cassette d'expression de sequences antisens et de ribozymes

Publications (1)

Publication Number Publication Date
EP0767834A1 true EP0767834A1 (fr) 1997-04-16

Family

ID=25938313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95919314A Ceased EP0767834A1 (fr) 1994-07-04 1995-05-19 Cassette d'expression de sequences antisens et de ribozymes

Country Status (4)

Country Link
US (2) US5695992A (fr)
EP (1) EP0767834A1 (fr)
DE (1) DE4424761C1 (fr)
WO (1) WO1996001315A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130092A (en) * 1994-07-04 2000-10-10 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Ribozyme gene library and method for making
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
FR2743818B1 (fr) * 1996-01-23 1998-04-10 Agronomique Inst Nat Rech Constructions d'adn et vecteurs d'expression derives du gene de l'arn va i d'adenovirus
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
DE10046913A1 (de) * 2000-09-21 2002-04-18 Nascacell Gmbh Expressionssystem für funktionale Nukleinsäuren
US8252527B2 (en) * 2007-02-16 2012-08-28 The Research Foundation Of State University Of New York Method for identification of polynucleotides capable of cleaving target mRNA sequences

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2090049T3 (es) * 1989-03-16 1996-10-16 Boehringer Ingelheim Int Unidades geneticas para la inhibicion de la funcion de arn.
FR2687411A1 (fr) * 1992-02-13 1993-08-20 Nice Sophia Antipolis Universi Vecteur comportant un gene viral transcrit par l'arn polymerase iii, et procede de production intracellulaire d'arn.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9601315A1 *

Also Published As

Publication number Publication date
WO1996001315A1 (fr) 1996-01-18
US5695992A (en) 1997-12-09
DE4424761C1 (de) 1995-06-08
USRE37411E1 (en) 2001-10-16

Similar Documents

Publication Publication Date Title
EP1798285B1 (fr) Méthode et médicament destinés à inhiber l'expression d'une gène donnée
DE69435005T2 (de) Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
DE69636937T2 (de) Durch trans-spaltung erhaltene therapeutische molekule
DE4424762C1 (de) Ribozym-Bibliothek, ihre Herstellung und ihre Verwendung
DE69233117T2 (de) In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen
EP1951870B1 (fr) Produits de recombinaison de l'adn pour l'inhibition specifique de l'expression de genes par interference arn
KR900014591A (ko) Rna 작용을 억제하는 유전 단위
WO2003035869A1 (fr) Utilisation d'un acide ribonucleique double brin pour inhiber de maniere ciblee l'expression d'un gene cible determine
EP2121922B1 (fr) Molécules biologiquement actives, notamment à base de pna et de sirna, procédé permettant leur activation à spécificité cellulaire, et kit d'application pour leur administration
WO2003062423A2 (fr) Procede d'inhibition de l'expression d'un gene cible issu d'une aberration chromosomique
DE4424761C1 (de) Expressionskassette für die Antisense- und die Ribozym-Expression
DE19520815C2 (de) Replikatives und transkriptionsaktives Peptid-Nukleinsäureplasmid, sowie seine Verwendung zur Einbringung in Zellen und Zellorganellen
DE60202196T2 (de) Orientationsgerichtete konstruktion von plasmiden
EP0299303B1 (fr) Vecteurs d'expression eucaryotiques avec des sous-unités "enhancer" multimériques, procédé pour la préparation et utilisation
AU784832B2 (en) Self-cleaving RNA sequences and their use for the control of protein synthesis
WO1997004087A1 (fr) Ribozymes pour l'inhibition selective de l'expression de genes d'alleles du complexe majeur d'histocompatibilite(cmh), et medicaments les contenant
DE102004038535B4 (de) Zelluläre Einschleusung von Nukleinsäurewirkstoffen
DE10211558A1 (de) Neue Formen RNAi
DE69933382T2 (de) Herstellung von ssdna innerhalb der zelle
DE19828624C1 (de) Modular aufgebaute RNA-Moleküle mit zwei Sequenzbereichstypen
DE19719200A1 (de) Regulation der Translationsinitiation in Eukaryotenzellen
EP3583215A1 (fr) Système et procédé de traduction spécifique d'un type cellulaire de molécules d'arn dans des eucaryotes,
EP2264173A2 (fr) Utilisation d'acide ribonucléique double-brin pour l'inhibition ciblée de l'expression d'un gène cible donné
EP1438409A1 (fr) Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DK FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20010926

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020727